Skip to main content
OpenTrials
Completed

NCT Number: NCT01498250

Microarray Analysis of microRNA Expression in Basal Cell Carcinoma

Perturbations in microRNA (miRNA) expression profiles has been reported for a variety of cancers. This study will be an exploratory analysis of miRNA expression in basal cell carcinoma by miRNA expression profiling using microarrays.

Completed

Looking for future studies?

Notify Me

Key information

Age range

1 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum

Bochum, North Rhine-Westphalia, 44791, Germany

About this study

Perturbations in the expression profiles of microRNAs (miRNAs) have been reported for a variety of different cancers. Basal cell carcinoma (BCC) of the skin has not been systematically evaluated regarding differentially expressed miRNAs. Patients with BCC are included in the study to perform an exploratory analysis by miRNA expression profiling using microarrays. Expression levels of miRNA candidates will be validated by TaqMan real-time quantitative polymerase chain reaction (RT-PCR).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Basal Cell Carcinoma

Exclusion criteria

  • Other Skin Cancer than Basal Cell Carcinoma

Sponsors and collaborators

Lead sponsor

Ruhr University of Bochum

Other

Registry information

Important dates

Study start
2011
Primary completion
2011
Study completion
2011
First posted
Dec 23, 2011
Registry last updated
Oct 16, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.